Navigation Links
Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets
Date:4/29/2009

ENDED MARCH 31, 2009 AND 2008 (Dollars in thousands) (UNAUDITED) Three Months Ended March 31 --------------- 2009 2008 ---- ---- Cash flows from operating activities: Net income $40,295 $49,102 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 19,614 17,348 Non-cash compensation expense associated with employee benefit and stock compensation plans 5,879 6,044 Deferred income tax benefit (1,840) (779) Gain on sale of business - (2,978) Loss on sale of property and equipment 166 13 Equity investee earnings (172) (449) Changes in operating assets and liabilities, net of business acquired: Accounts receivable (29,151) (2,532) Unbilled services 9,808 (7,280) Inventory (6,401) (4,051) Accounts payable 944 1,215 Accrued liabilities (36,361) (19,542) Unearned revenue 8,214 (5,539) Income taxes payable 9,535 11,177 Other assets and liabilities, net (11,301) (5,957) ------- ------
'/>"/>
SOURCE Covance Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Covance Opens New Clinical Development Offices in Chile, Peru and Expands Argentina Office
2. Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc
3. Covance Increases Early Clinical Footprint in Europe with Acquisition of Swiss-Based Early Clinical Development Site
4. Covance Purchases Equity Stake in Caprion Proteomics
5. Covance and Lilly Finalize 10-Year, $1.6 Billion Strategic R&D Collaboration
6. Covance Decides to Pursue Its Original Preclinical Strategy in China
7. Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China
8. Covance to Present at The R.W. Baird 2008 Growth Stock Conference
9. Covance to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
10. Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
11. Covance Inc. Invites You to Join the Webcast of Its Third Quarter 2007 Financial Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... LONDON and BOSTON , June ... market is set to reach $127 billion by 2018, accounting ... to the recently released Orphan Drug Report 2013 ... its clients, needs in regard to this growing segment of ... core product database to include in-depth, fact-based orphan drug analysis ...
(Date:6/17/2013)... June 17, 2013 With the huge success ... of the Chief Medical Officer Summit for Emerging Life Science ... take place in San Francisco on November 4-5, 2013 at ... first time, West Coast Chief Medical Officers at biotechs have ... Stoner, Managing Director of MPM Capital. Valerie Bowling, Executive Director ...
(Date:6/17/2013)... MUNDELEIN, Ill. , June 17, 2013 /PRNewswire/ ... – News), a biotechnology company providing value-added ingredients ... it will be presenting a new meat application ... (IFT) show in Chicago , ... Trim ingredients can replace more expensive/chemically-modified ingredients in ...
(Date:6/17/2013)... DUBLIN , June 17, 2013 /PRNewswire/ ... http://www.researchandmarkets.com/research/9rwvs2/north_america ) has announced the addition of ... Market - by Formulations [Liposomes, Microspheres, & ... Prefilled, Pen, Needle Free & Auto Injectors] ... to their offering. ,      ...
Breaking Biology Technology:Evaluate Launches Enhanced Orphan Drug Intelligence 2Evaluate Launches Enhanced Orphan Drug Intelligence 3Chief Medical Officer Summit for Biotechs Goes West 2Chief Medical Officer Summit for Biotechs Goes West 3Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago 2Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago 3North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 2North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 3
... N.J., Dec. 17 National Stem,Cell Holding, Inc. ... financial information, quotations and press releases are,posted on ... OTCIQ is a secure, web-based portal that ... facilitate communication with the,marketplace, promote transparency, mitigate risk, ...
... Genzyme Corp.,(Nasdaq: GENZ ) announced today that ... a supplemental indication for Thyrogen(R) (thyrotropin,alfa for injection) ... ablate,or destroy, the remaining thyroid tissue in patients ... is a procedure that patients,commonly undergo when being ...
... DIEGO, Dec. 17 SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ... appointed to,the company,s Board of Directors. Mr. Turner brings ... and will also serve on,the company,s audit committee., ... said Dr. Christopher S.,Henney, Chairman of the Board of ...
Cached Biology Technology:National Stem Cell Holding, Inc. Posts Company and Financial Information on the OTCIQ and Has Retained New CFO and Counsel to File Registration Statement With SEC 2Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation 2Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation 3Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation 4SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors 2SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors 3
(Date:6/14/2013)... Cliffs of Dover" was a morale-boosting song that lifted ... mark the point at which England is closest to ... structures made of the chalky, white shells that envelop ... . "Ehux" is a coccolithophore, with an exoskeleton made ... the alga,s "armor" forms releases carbon dioxide, Ehux can ...
(Date:6/14/2013)... 12 June 2013: Data presented at EULAR 2013, the ... that novel antibody biomarkers could significantly improve diagnosis in ... UH-RA.1, UH-RA.9, UH-RA.14 and UH-RA.21 were investigated; as ... were present in both early and seronegative disease, ... and ACCP -negative patients testing positive. , RA ...
(Date:6/13/2013)... that combining improved oyster restoration methods with limits on ... population back to the Bay in a much shorter ... of the University of Maryland Center for Environmental Science,s ... restoration options to see which ones would have the ... we developed suggests that oysters should be able to ...
Breaking Biology News(10 mins):Chalking up a marine blooming alga: Genome fills a gap in the tree of life 2Chalking up a marine blooming alga: Genome fills a gap in the tree of life 3Chalking up a marine blooming alga: Genome fills a gap in the tree of life 4Oysters could rebound more quickly with limited fishing and improved habitat 2
... remains the subject of "best guesses," and as a ... perceptions and politics, rather than an objective assessment of ... , Simon Hay and Robert Snow (Kenya Medical Research ... been almost 40 years since the last global map ...
... be arranged along a ladder of intelligence—a sort of ... by our close relatives, the primates, all the way ... past decade, this ladder has been challenged by claims ... animals. For example, spotted hyenas establish hierarchies in which ...
... fight viruses is also involved in keeping cancer cells alive, ... The anti-viral molecule, called TBK-1, was found to be essential ... to a treatment for fighting cancer, the researchers report in ... surprise that this mechanism is involved in cancer cell survival, ...
Cached Biology News:Fishy cooperation 2Natural anti-viral enzyme helps keep cancer cells alive, researchers find 2
... IgY Antibodies Hypothetical protein FLJ20644, likely ... Protein Accession #: NP_060387.1 ... Genbank Definition: chromosome 14 open ... phosphatase subunit gene g4-1 [Homo sapiens] ...
Request Info...
Lineage cocktail 1 (lin 1) 50 tests...
Contained in EZ-Tn5™ Kits and are available separately for sequencing of an insertion site....
Biology Products: